Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Recent pharma exec shake-ups signal strategic shifts

Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.

By Kelly Bilodeau • June 24, 2026

Pfizer CFO departs for consumer goods sector

Dave Denton joined Pfizer in 2022 from Lowe’s Companies and is leaving for an unspecified “professional opportunity” in consumer goods, the company said.

By Maura Webber Sadovi • Updated June 18, 2026

As M&A rebounds, here’s how pharmas can prepare to seal a deal

Drugmakers that aren’t ready when financial opportunity knocks could get caught flat-footed in a competitive market.

By Kelly Bilodeau • June 18, 2026

The biotech market is rebounding. So where are the executive jobs?

The industry is showing favorable economic signs, but biotech companies are still taking a measured approach to hiring leaders.

By Kelly Bilodeau • June 15, 2026

The ‘secret sauce’ for hiring for biotech CEOs

Biotech company architect Stella Vnook shares her formula for finding the right chief executives.

By Alexandra Pecci • May 27, 2026

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

By Jacob Bell • May 27, 2026

China’s biotech rise sparks new US industry alliance

The nonprofit is aiming to inspire a new moonshot effort that helps the U.S. maintain its position as a drug innovation leader.

By Kelly Bilodeau • May 21, 2026

Summer reads with unexpected lessons for biopharma leaders

From an inspiring rags-to-riches journey to a heroic rescue story at sea, here are a few books recommended by biopharma execs and what they can teach about leadership.

By Alexandra Pecci • May 19, 2026

HHS, industry leaders spar over drug pricing, TrumpRx and PBMs

Debate about drug costs erupted among prominent healthcare figures, including Dr. Oz, Mark Cuban, Calley Means and PhRMA in Washington, D.C., but they all agreed on one thing: The system is broken.

By Michael Gibney • April 23, 2026

Who is Dr. Houman Hemmati, potentially CBER’s next leader?

Where the rumored frontrunner stands on key issues like vaccines and public health policy.

By Kelly Bilodeau • April 20, 2026

Roche’s DAC investment; Big Pharma’s lavish CEO bumps

Roche is investing in new cancer-fighting technology, and some of Big Pharma's CEOs notched some noteworthy pay hikes.

By PharmaVoice Staff • April 17, 2026

How J&J plans to hit $100B in revenue this year

Johnson & Johnson leaders have laid out a plan to reach record revenue this year while opening the door to more down the road.

By Michael Gibney • April 16, 2026

5 notable pharma CEO pay hikes in 2025

Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.”

By Alexandra Pecci • April 14, 2026

One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it.

Dr. Ebrahim Delpassand, founder and CEO of RadioMedix, played a pivotal role in advancing nuclear medicine as a new-generation cancer treatment, but his work is far from finished.

By Michael Gibney • April 9, 2026

Boehringer Ingelheim’s confident new leap in the obesity market

With weight loss candidates still in the clinic, the company has launched a health unit aimed at the flourishing therapeutic area.

By Alexandra Pecci • April 7, 2026

The FDA’s shame game

The agency is becoming more open about its criticisms of pharma companies and leaders, raising new privacy concerns in the industry.

By Kelly Bilodeau • March 30, 2026

Women in biotech hit a leadership plateau as board barriers persist

A new initiative from BioIndustry Association and AstraZeneca aims to boost representation on heavily dominated male boards.

By Alexandra Pecci • March 24, 2026

Executives want in, but researchers want out — how pharma’s US job picture is changing

While academics are eyeing friendlier work opportunities abroad, America’s manufacturing boom is drawing industry leaders to its shores.

By Alexandra Pecci • March 10, 2026

Biopharma’s recent string of CEO splits

Leaders at Bavarian Nordic, Sarepta and Alkermes recently announced plans to step down.

By Meagan Parrish • March 6, 2026

Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off.

Moderna’s clash with U.S. health agencies over its flu shot reflects a difficult time for vaccinemakers, but many are still playing the waiting game.

By Michael Gibney • Feb. 19, 2026

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration.

By Kristin Jensen • Feb. 13, 2026

Ovid takes another big swing in neuroscience under a new CEO

After multiple setbacks, the company is chasing a CNS target it believes has “revolutionary” potential.

By Meagan Parrish • Feb. 13, 2026

In a tough market, biotechs can be their own worst enemy

Even with sound science, startups can struggle to make their candidates go the distance.

By Alexandra Pecci • Feb. 10, 2026